Use of high doses of deferoxamine (desferal) in an adult patient with acute iron overdosage

Martha G. Peck, John F. Rogers, James F. Rivenbark

Research output: Contribution to journalArticle

Abstract

Deferoxamine, a specific chelator of ferric iron, has recognized efficacy in the treatment of acute iron overdosage. Toxicological references, however, vary in the preferred route of administration and recommended maximum dosage. A 19-year-old female patient ingested an estimated 50-60 ferrous sulfate tablets, representing approximately 9.8-11.7 g of elemental iron. At the time of admission, she had a serum iron level of 915 μg/dL and a total iron binding capacity of 515 μg/dL. She was treated with intravenous deferoxamine at 15 mg/kg/h via continuous infusion for a total dose of 37.1 g over a 52-h period until her urine exhibited no evidence of deferoxamine-iron chelation products for 24 consecutive hours. This paper supports the safety and efficacy of a slow IV infusion of deferoxamine in an adult patient, using a regimen recommended for pediatric patients.

Original languageEnglish (US)
Pages (from-to)865-869
Number of pages5
JournalClinical Toxicology
Volume19
Issue number8
DOIs
StatePublished - 1982
Externally publishedYes

Fingerprint

Deferoxamine
Iron
ferrous sulfate
Pediatrics
Chelating Agents
Chelation
Toxicology
Tablets
Urine
Safety
Serum

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Use of high doses of deferoxamine (desferal) in an adult patient with acute iron overdosage. / Peck, Martha G.; Rogers, John F.; Rivenbark, James F.

In: Clinical Toxicology, Vol. 19, No. 8, 1982, p. 865-869.

Research output: Contribution to journalArticle

Peck, Martha G. ; Rogers, John F. ; Rivenbark, James F. / Use of high doses of deferoxamine (desferal) in an adult patient with acute iron overdosage. In: Clinical Toxicology. 1982 ; Vol. 19, No. 8. pp. 865-869.
@article{16ad831b974140a385f66120e5e3b5c4,
title = "Use of high doses of deferoxamine (desferal) in an adult patient with acute iron overdosage",
abstract = "Deferoxamine, a specific chelator of ferric iron, has recognized efficacy in the treatment of acute iron overdosage. Toxicological references, however, vary in the preferred route of administration and recommended maximum dosage. A 19-year-old female patient ingested an estimated 50-60 ferrous sulfate tablets, representing approximately 9.8-11.7 g of elemental iron. At the time of admission, she had a serum iron level of 915 μg/dL and a total iron binding capacity of 515 μg/dL. She was treated with intravenous deferoxamine at 15 mg/kg/h via continuous infusion for a total dose of 37.1 g over a 52-h period until her urine exhibited no evidence of deferoxamine-iron chelation products for 24 consecutive hours. This paper supports the safety and efficacy of a slow IV infusion of deferoxamine in an adult patient, using a regimen recommended for pediatric patients.",
author = "Peck, {Martha G.} and Rogers, {John F.} and Rivenbark, {James F.}",
year = "1982",
doi = "10.3109/15563658208992521",
language = "English (US)",
volume = "19",
pages = "865--869",
journal = "Clinical Toxicology",
issn = "1556-3650",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Use of high doses of deferoxamine (desferal) in an adult patient with acute iron overdosage

AU - Peck, Martha G.

AU - Rogers, John F.

AU - Rivenbark, James F.

PY - 1982

Y1 - 1982

N2 - Deferoxamine, a specific chelator of ferric iron, has recognized efficacy in the treatment of acute iron overdosage. Toxicological references, however, vary in the preferred route of administration and recommended maximum dosage. A 19-year-old female patient ingested an estimated 50-60 ferrous sulfate tablets, representing approximately 9.8-11.7 g of elemental iron. At the time of admission, she had a serum iron level of 915 μg/dL and a total iron binding capacity of 515 μg/dL. She was treated with intravenous deferoxamine at 15 mg/kg/h via continuous infusion for a total dose of 37.1 g over a 52-h period until her urine exhibited no evidence of deferoxamine-iron chelation products for 24 consecutive hours. This paper supports the safety and efficacy of a slow IV infusion of deferoxamine in an adult patient, using a regimen recommended for pediatric patients.

AB - Deferoxamine, a specific chelator of ferric iron, has recognized efficacy in the treatment of acute iron overdosage. Toxicological references, however, vary in the preferred route of administration and recommended maximum dosage. A 19-year-old female patient ingested an estimated 50-60 ferrous sulfate tablets, representing approximately 9.8-11.7 g of elemental iron. At the time of admission, she had a serum iron level of 915 μg/dL and a total iron binding capacity of 515 μg/dL. She was treated with intravenous deferoxamine at 15 mg/kg/h via continuous infusion for a total dose of 37.1 g over a 52-h period until her urine exhibited no evidence of deferoxamine-iron chelation products for 24 consecutive hours. This paper supports the safety and efficacy of a slow IV infusion of deferoxamine in an adult patient, using a regimen recommended for pediatric patients.

UR - http://www.scopus.com/inward/record.url?scp=0020285724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020285724&partnerID=8YFLogxK

U2 - 10.3109/15563658208992521

DO - 10.3109/15563658208992521

M3 - Article

C2 - 7182516

AN - SCOPUS:0020285724

VL - 19

SP - 865

EP - 869

JO - Clinical Toxicology

JF - Clinical Toxicology

SN - 1556-3650

IS - 8

ER -